Hospira Stock Rebounds In Second Quarter; Index Off 1.5%
This article was originally published in The Gray Sheet
Executive Summary
Hospital product manufacturer Hospira's release of stronger-than-expected financial results in the second quarter drove an 8.8% rebound in the firm's stock price to $42.94 for the period - a $3.49 gain over Q1
You may also be interested in...
DoJ Probes Big Orthopedic Firms’ Pricing, Deflating Investor Confidence
The U.S. Department of Justice served subpoenas to the five largest orthopedic manufacturers to investigate suspected industry violations of antitrust laws in pricing hip and knee implants. The specific nature of the inquiry is unknown
Baxter’s Colleague Consent Decree Enjoins Sales, Expands Obligations
Baxter signed a consent decree with FDA June 29 forbidding the sale of its widely used but malfunction-prone Colleague intravenous infusion pump until the firm complies with manufacturing quality regulations
Siemens Won $1.86 Bil. DPC Deal By Outbidding Two Other Firms
Siemens' successful bid to acquire Diagnostic Products Corp. earlier this spring was more than a year in the making, according to a recent DPC merger proxy statement